UK’s Early Value Assessment Pilot Is ‘Catalyst’ For Wider Change - NICE
Executive Summary
NICE’s early value assessment (EVA) pilot for medtech will have failed unless it changes the way that medical devices “as a whole” are evaluated in the UK, according to Mark Chapman, the organization’s interim director of medical technology.
You may also be interested in...
NICE Launches ‘Concierge System’ To Guide Companies Through HTA Process
The health technology assessment body for England and Wales has launched an integrated, flexible advice portal to help guide companies through its potentially “bewildering” health system.
NICE Launches ‘Concierge System’ To Guide Companies Through HTA Process
The health technology assessment body for England and Wales has launched an integrated, flexible advice portal to help guide companies through its potentially “bewildering” health system.
As Digital Medtech Innovations Speed Ahead, How Can The UK Regulator Keep Up?
Digital health technologies are evolving rapidly, but UK regulation is lagging behind. Using international standards “as default” could go some way to closing this gap, according to a report by UK medtech trade body ABHI.